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Table 1 • Disease-linked haplotypes of families with a recurrent deletion mutation
Family Proband's
diagnosis3 THRA1
Linked allele lengthb at polymo 
D17S855 D17S1322
rphic marker (bp) 
D17S1323 D17S1327
3,835-bp deletion:
B20 Br43 169/167 151/145 122/128 151/159 133/169
EUR9 Br28/Br46 169 151 122/128 151 133
EUR18 Ov54 169 151 122 151 133
EUR19 Ov38 169 151/153 122 151 133
EUR31 Ov36/Br43/Br49 169 151 122 151 133
Allele frequency*1 0.08 0.21 0.51 0.68 0.60
510-bp deletion:
RUL5 Br41 167 155 122 151 133
RUL16 Br41/Ov48 167 155 122 151 133
RUL20 Br64 167 155 122 151 133
RUL78 Br31 167 155 122 151 133
RUL80 Br41 167 155 122 151 133
RUL97 Br35/Br52 167/169 155/149 122/125 151/157 133/157
RUL1Q5 Ov4Q 171 155 122 151 133
EUR52 0v50 167 155 122 151 133
Allele frequency0 0.19 0.09 0.51 0.68 0.60
IVS22 + 5G->A; 
EUR21 Br41 167 149 125 151 155
Allele frequency0 0.19 0.16 0.25 0.68 0.02
aBr43 indicates that age of onset of breast cancer was 43 y; Ov54 indicates that age of onset of ovarian cancer was 54 y, bWhen marker was uninformative to 
determine phasing, both alleles are listed. cOf most commonly shared allele only, as measured among 158 unrelated Dutch control individuals4.
been reported Lo occur somatically in breast tumours14,15, Alu- 
mediated large genomic deletions might be a more common 
mechanism that inactivates BRCA1 in sporadic breast cancer.
Because strong founder effects have been observed for many 
BRCA1 mutations detected worldwide5,6, large deletions may con­
stitute a substantial proportion of the mutation spectrum in cer­
tain ethnic subpopulations, as evidenced here for the Dutch. This 
could explain the discrepancy between the proportion of BRCAÎ 
mutations predicted by linkage studies16,17 and the actual preva­
lence established by mutation analysis of breast-cancer families 
derived from a variety of ethnic backgrounds6,18"22. Although such 
deletions are detectable by RT-PCR analysis, the latter has not yet 
been widely used for mutation detection, and might be prone to 
false-negative results (for instance, as seen in the case of EUR9.5), 
either because the low abundance of BRCA1 mRNA in lympho­
cytes causes coincidental preferential amplification of the wild-type 
transcript (Fig. lb) or because transcripts carrying exonic deletions 
are more unstable than the full-length transcript12. Our data clearly 
show that a comprehensive BRCAl mutation test should include 
the examination of its genomic structure.
Methods
Family ascertainment. Research families were ascertained either by the 
Netherlands Foundation for the Detection of Hereditary Tumors or by 
the Rotterdam Family Cancer Clinic. They all contain at least three first- 
degree relatives with either breast or ovarian cancer, at least one of them 
having received a diagnosis before 50 years of age. Of the 170 thus 
recruited, there were 48 families with at least four cases of breast cancer 
diagnosed before age 60, in addition to any number of ovarian cancers4. 
Patients entered the study by application or physician referral to a family 
cancer clinic or clinical genetics department in either Amsterdam or 
Leiden. In general, these patients have an a priori chance of 10% or 
higher of being carriers of a BRCAl mutation23.
DNA and RNA isolation, reverse transcription and nested PCR. isolation 
of genomic DNA and total RNA from fresh blood samples and preparation 
of first-strand cDNA by reverse transcription have been described7. For 
the RT-PCR analysis of exons 12-24, we used the following primers for the 
first PCR: forward (F), 5 -TCACAGTG CAGTGAATTGGAAG-3'; reverse 
(R), 5'-GTAGCCAGGACAGTAGAAGGACTG-3'. Nested primers were 
then used in a subsequent PCR to amplify exons 12-24 (F, 5 '-GAAGAAA-
GAGGAACGGGCTTGG-3 R, 5 -GGCCACTTTGTAAGCTCATTC-3'). 
For nested PCR of exons 20-24, the same reverse primer was used in com­
bination with the F: 5-AACCACCAAGGTCCAAAGC-3'. PCR condi­
tions were as described previously7.
Genomic PCR of the deletions spanning exons 13 or 22, A PCR reaction 
of 50 ml typically contained 200 ng of genomic DNA, 10-pmol primers, 
0.75 U AmpliTaq Taq polymerase (Perkin Elmer/Cetus) and 5 ml of either 
X10 RM buffer (500 mM KCl, 100 mM TRIS-HCI pH 8.4, 25 mM MgCU,
2 mg/ml BSA, 2 mM dNTPs) for exon 13 or Optiprime buffer #6 
(Stratagene), supplemented with 0.1 mM dNTPs for exon 22. For exon 13, 
the primers were (F) 5 -C  AAT GT GTTCCTG CCCTACT-3 ' and (R)
5 -AC ACTG G A AG AC A AC AG ATATTA A-3 while an internal control 
fragment from exon 11 was co-amplified simultaneously (primers F,
5 -GTACAGTGAGCACAATTACCCG-3'; R, 5 '-TCTCAG A AC AA ACCT - 
GAGATGC-3'). This mixture was heated at 94 °C for 1 min, followed by 32 
cycles of PCR (1 min at 94 °C, 1.5 min at 56 °C and 2 min at 73 °C) on a 
Perkin Elmer/Cetus DNA thermal cycler. For exon 22, the primers were (F)
5-TCCCATTGAGAGGTCTTGCT-3' and (R) 5 -ACTGTGCTACT-
CAAGCACCA-3'. After heating at 94 °C for 5 min, the PCR consisted of 
35 cycles (45 s at 94 °C, 1 min at 52 °C and 2.5 min at 72 °C), All PCRs were 
concluded by an incubation at 73 °C for 4 min. The PCR products (5 ml) 
were analysed on a 1.5% agarose gel.
Southern analysis. Genomic DNA (5 jig) was digested with BglU or 
H in á lll  according to the supplier’s protocols (Pharmacia). Agarose gels 
(0.8%) were run at 30 V for 16 h in TAE buffer (40 mM Tris-H Ac pH 8.3, 1 
mM EDTA). Procedures for denaturing and transferring the separated 
DNA to nylon membranes (Hybond N+, Amersham) have been previously 
described24. As probes we used PCR products obtained from a clone con­
taining the complete BRCAl cDNA, and purified with the QIAquick PCR 
Purification Kit (Qiagen). Probe 11 (pi 1 ) derives entirely from exon II 
and was obtained with the primers (F) 5'-GAAAAAAAAGTACAAC- 
CAAATGCC-3' and (R) 5 -AG CCCACTTC ATTAGTACTG G A AC-3 '.
Probe 1424 (p i424) contains exons 14-24 and was obtained with the 
primers (F) 5 -TAC CCTATA AG CC AG A ATC CAGA A-3 ' and (R) 5-G G C- 
CACTTTGTAAGCTCATTC-3'. Purified fragments were labelled using 
the Megaprime DNA labelling system (Amersham) according to the sup­
plier’s protocols. Hybridizations were carried out overnight at 65 °C in 
125 mM Na2I-IP04*2H20, 7% SDS, 10% PEG-6000, 1 mM EDTA. Final 
washes were in 45 mM NaCl, 4.5 mM Na citrate pH 7.0,0.1 % SDS, at 65 °C 
for 30 min. Filters were exposed overnight to a Phosphorlmagcr screen 
(ImageQuant, Molecular Dynamics) and subsequently to Kodak X-Omat 
autoradiograms for 3 days a t -70 °C.
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Sequencing. Direct sequencing of PCR fragments was performed with 
M13-tailed and biotinylated primers used for PCR and subsequent solid- 
phase sequencing with ftuoresceinated primers on a Pharmacia A.L.R 
Sequencer. Primer sequences have been published previously25.
Polymorphic marker analysis. Five polymorphic microsatellite markers 
located on chromosome 17q, spanning an approximately 3-cM intcival 
including BRCAl, were used in a radioactive PCR under conditions 
described elsewhere4. D17S1323 has been mapped to intron 12 of BRCAl, 
D17S1322 to intron 19, and D17S855 to intron 20 (ref. 10). THRA1 is 
approximately 2 cM proximal of BRCA I , and DI7S1327100 kb distal5,16 to 
BRCAL CEPH sample 1347 was used as a reference to estimate the size of 
alleles in base pairs.
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